737 Interim results of a first-in-human phase 1 dose-escalation trial of TAK-102, a glypican-3 targeted armored chimeric antigen receptor T-cell immunotherapy in patients with advanced solid tumors | Zendy

AI Assistant Blog Pricing

737 Interim results of a first-in-human phase 1 dose-escalation trial of TAK-102, a glypican-3 targeted armored chimeric antigen receptor T-cell immunotherapy in patients with advanced solid tumors

Details

The content you want is available to Zendy users.Already have an account? Click here. to sign in.